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As a result of immunological studies of the last 25 years it turned out that interleukin-7 (IL-7) is one of the most
important regulatory cytokines of the immune system. It is special in many concerns. Having a strong impact on
the development, proliferation and activation of immune cells it is, however, cannot be attributed to the classic
cytokine-activators, like IL-2, as many types of cells require its presence at almost all stages of the development,
and its spectrum of activities is impressive. The review aims to summarise the numerous data obtained on the
IL-7 structure, biological activity, biological significance and features of functioning studied both in vitro and in
vivo. We made the main emphasis on the IL-7 signal transduction pathways that determine the fate of T and B cells,
as well as some other cells important for homeostasis of the organism. In our opinion, the analysis of literature in
this field not only reveals a host of questions still unanswered, but also makes the path for perspective investiga-
tion more visible.
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Introduction. In recent years, considerable attention has
been paid to studying the mechanisms of communica-
tion between different cell types important for the inte-
grity and homeostasis of the organism. An unusually
large number of signaling molecules were discovered
including their receptors and intracellular messengers
involved in either the activation or suppression of va-
rious genes influencing functional behavior of the cell.
All these molecules form an incredibly complicated sig-
naling network exploiting the principles of overlap-
ping, amplification or turning off certain signaling path-
ways and elements. One of the most complicated signa-
ling networks is a cytokine signaling network.
Cytokines are special signaling glycoproteins be-
longing to the immune system and having molecular
weight less than 30 kDa. They are released into the
blood and lymph mainly by T cells and act at very low
concentration (10–12 M).
However, in addition to T cells, cytokines are pro-
duced by broad range of cells, including immune cells
like macrophages, B lymphocytes and mast cells, as
well as endothelial cells, fibroblasts, and various stro-
mal cells; a given cytokine may be produced by more
than one type of cell [1]. In total, there are over 100 cy-
tokines, that are classified according to their functions
into interferons, interleukins, colony stimulating factors,
chemokines and tumor necrosis factors. It is considered
that the interleukins (ILs) family comprises 37 mem-
bers (IL-1-37); however, currently more than 40 cytoki-
nes are designated as ILs.
This review is dedicated to a special member of the
gamma-chain cytokine family – interleukin-7 (IL-7). It
was discovered at Immunex Research and Develop-
ment corporation in 1988 [2]. Human cDNA was first
cloned in 1989 [3]. Numerous studies revealed that
IL-7 is a nonredundant hematopoetic cytokine, which
plays a crucial role in the development and homeostasis
of many types of immune cells.
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Here we try to encompass the latest data about the
mechanisms of signal transduction that allow revealing
an intricate network of interactions of IL-7 with other
cytokine signaling systems. In spite of considerable in-
formation obtained on IL-7, still only few data on the ro-
le of interaction between IL-7 and other signaling mole-
cules are available and need to be reviewed, as well as
some other aspects of its biological effects.
Interleukin-7 molecular structure. Interleukin-7
is a single chain 25kD glycoprotein containing 4 heli-
ces that are internally disulfide cross-linked. Hydropho-
bic core of human IL-7 is formed by amino acids L16,
M17, I20, L23, L24 (helix A), F55, L56, A59, L63, F66
(helix B), L79, V82, T86, L89, T93 (helix C), L128,
L131, L135, I138 and W142 (helix D). As it is typical
for hematopoietic cytokines, amino acid residues of si-
de sequences are also parts of the core of the molecule.
In case of IL-7 they are M27, F39, F41, F42 (loop AB)
and F75 (loop BC) [4].
Human IL-7 gene is located at 8q12-q13 chromo-
some. The length of this gene is about 33 kb and it con-
tains 6 exons and 5 introns. The protein product of the
IL-7 gene has molecular weight of 17.4 kDa, but after
N-glycosilation at three sites (Asn95, Asn116 and Asn
141) it reaches 25 kDa.
IL-7 molecule contains six cysteine residues, which
make three intramolecular disulphide bonds (Cys 34–
Cys 129, Cys 47–Cys 141 and Cys 2–Cys 92). IL-7 mo-
lecule displays very high stability even with extreme pH
variation (from 2.1 to 8.0) [5]. However, it loses its bio-
logical activity after the addition of -mercaptoethanol,
pointing to the importance of disulfide bonds [6]. Up to
6 isoforms have been described as the products of alter-
native splicing, and predictions of their structure have
been generated. There are three additional in-frame spli-
ce variants, which lack exons either 3 or 5 or both and
exon 4, respectively: IL-7delta3/4, IL-7delta4/5 and
IL-7delta3/4/5. Also three out-of-frame splice variants
were found: IL-7 (–56 bp exon 2), IL-7delta4 (–56 bp
exon 2), and IL-7delta3/4/5 (–56 bp exon 2), which,
besides the aforementioned exon deletions, miss 56 bp
at the 3' end of exon 2 [7]. The biological properties of
IL-7 splice variants are poorly investigated.
Sites and regulation of production. Production of
IL-7 has been detected in multiple stromal tissues, inclu-
ding the thymus and bone marrow [8, 9]. Within the thy-
mus, the predominant cell responsible for IL-7 produc-
tion appears to be a major histocompatibility complex
(MHC) class II+ epithelial cell that likely represents a
cortical epithelial cell [10]. The additional sites of IL-7
production include intestinal epithelium, keratinocy-
tes, fetal liver, adult liver, dendritic cells and follicular
dendritic cells [11–17]. Thus, IL-7 is essentially a tissue-
derived cytokine, with the primary sources in stromal
and epithelial cells of various locations, whereas bone
marrow-derived dendritic cells appear to be relatively
minor sources of IL-7.
Biological effects of IL-7. Originally, IL-7 was des-
cribed as a pre-B cell growth factor (lymphopoietin-1)
found in the supernatant of the bone marrow-derived
stromal cells [18]. However, the studies soon followed
demonstrated that in vitro IL-7 was also important for
mature T cell and thymocyte growth. Subsequently, in
vivo studies have shown that IL-7 plays an important
role in the T cell development [19], mature T cell homeo-
stasis [20] and the development of so called lymphoid
tissue inducer cells (LTi cells) [21], playing a key role
in the development of lymph nodes and Peyer's patches
[22]. IL-7 is also important for dendritic cells (DCs) [23]
and natural killer cells (NK cells) [24]. Defciencies in
IL-7 or any component of IL-7R in mice result in seve-
rely impaired B and T lymphopoiesis [25].
Interleukin-7 receptor (IL-7R). IL-7 mediates its
effects via engagement of specific receptor, IL-7R – a
heterodimer comprised of IL-7R (also known as
CD127) and the common cytokine receptor -chain (c,
also known as CD132), and mediates anti-apoptotic and
co-stimulatory proliferative signals. As summarized in
Fig. 1, IL-7-mediated signaling participates in the T cell
receptor (TCR) gene rearrangement through DNA de-
methylation and histone acetylation during the T cell de-
velopment in the thymus. IL-7-mediated signaling ini-
tiates downstream signaling pathways through Janus
kinase 1 (Jak1), Jak3 and phosphatidylinositol-3-kina-
se (PI3K), resulting in phosphorylation and activation
of signal transducer and activator of transcription 5
(STAT5).
This results in changes in the expression of B cell
lym phoma 2 (Bcl-2) family members, such as increa-
sed expression of the anti-apoptotic molecules Bcl- 2
and Mcl1 (myeloid cell leukaemia sequence 1) and de-
creased expression of the pro-apoptotic molecules BAX
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(Bcl-2-associated X protein), BIM (Bcl-2-interacting
mediator of cell death) and BAD (Bcl-2 antagonist of
cell death). IL-7-mediated signaling in T cells also leads
to decreased levels of the cyclin-dependent kinase inhi-
bitor p27 (also known as p27Kip1), increased levels of
CDC25A (cell division cycle 25 homologue A) and chan-
ges in the expression of TCR modulators such as Casitas
B-lineage lymphoma B (CBL-B). The results of IL-7-
me diated signaling are increased T cell survival, increa-
sed proliferation, augmented TCR signals and, for recent
thymic emigrants, TCR-independent proliferation. In
contrast to other members of the c cytokine receptor fa-
mily, which are upregulated upon T cell activation and/
or cytokine signaling, IL-7R is expressed mostly by
resting T cells and is downregulated following IL-7-
mediated signaling and/or T cell activation [26, 27].
The molecular weight of IL-7R protein is about 121
kDa. Both IL-7R and c have a pair of conserved extra-
cellular cysteine residues and an extracellular Trp-Ser-
X-Trp-Ser motif and lack the intrinsic tyrosine kinase
activity and two partially conserved regions in the mem-
brane-proximal part of their intracellular domains. The
c chain augments IL-7 binding to IL-7R chain. The
IL-7R protein exists in two isoforms: membrane-
bound and soluble forms. The membrane-bound iso-
form is also found on the cell surface in association
with IL-2Rc [28]. Binding assays have demonstrated
the presence of two IL-7 receptor affinities: a high (Kd ~
10–10 M) and a low (Kd ~10
–8 M) affinity. It has been
also demonstrated that IL-7 can induce signal transduc-
tion events in cells that do not express IL-7R because of
its capacity to engage other surface receptors such as
Flt3 and c-kit [29].
IL-7R is a transmembrane heterotypic cytokine re-
ceptor belonging to the cytokine receptor homology
class 1 (CRH1) family and to the c family. c functions
as the activating receptor for IL-2, IL-4, IL-7, IL-9, IL-15,
and IL-21 [30]. Full-length human IL-7R consists of a
219-residue extracellular domain (ECD), a 25-residue
transmembrane domain (TMD), and a 195-residue in-
tracellular domain (ICD) [31]. IL-7 signaling was initial-
ly thought to function via the classical stepwise cytokine-
induced receptor heterodimerization way [32]. By this
mechanism, IL-7 interacts with the IL-7R ECD, for-
ming a 1:1 assembly, which subsequently recruits c,
producing the signaling complex. However, the classi-
cal paradigm was questioned when IL-7R homodi-
mers and IL-7R–c heterodimers were demonstrated
on T cells in the absence of IL-7. Neither the preassemb-
ly of IL-7R homodimers nor IL-7R–c heterodimers
induced signaling [33].
IL-7R ligand binding. IL-7R homodimer con-
sists of two IL-7R molecules packed against each other
with pseudotwofold symmetry (Fig. 2). This structure
explains why homodimerization of IL-7R does not ac-
tivate either IL-7 or TSLP signaling pathways. The ave-
rage distance between the C-terminal domains of the /
receptors and c is 27. Similar distance between the C-
terminal domains of IL-7R and c in an activating
complex was predicted. However, the distance between
the C-terminal domains of the homodimeric IL-7R struc-
ture is 110. It means that the Jak1 molecules bound to
the IL-7R ICDs are not able to activate each other be-
cause of the distance between them. The investigations
demonstrated a stronger binding affnity between the full-
length IL-7R and c than between the IL-7R in a ho-
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Fig. 1. IL-7-mediated signaling
pathways (adopted from [27])
modimer on T cells at 37 °C [33]. The following studies
showed that there is a stronger binding affnity for hete-
rodimerization of the IL-7R–c ECDs than for homo-
dimerization of the IL-7R ECDs (Kd of 3.1 	M vs >
610 	M at 25 °C) [34].
As it has been already stated, the IL-7R homodi-
mer keeps the Jak1 molecules bound to the ICDs separa-
ted by 110 . Likewise, the IL-7R–c heterodimer
would keep Jak1 and Jak3 separated by a large distance
preventing activation. When IL-7 binds both IL-7R
and c, the receptors undergo 90° rotation away from
the cell surface, bringing the two C termini of IL-7R
and c at a distance less than 30  and activating signal
transduction [34].
The spontaneously formed 1:1 heterodimers of IL-
7R and c (1:1 stoichiometry) at the surface of living
human CD4+ T cells in the absence of IL-7 also were
described. IL-7R is abundant on the resting human
CD4+ T cells (108 pmol/m2), but c is present at low con-
centrations (12 pmol/m2) and thus restricts the heterodi-
mer formation (10 pmol/m2) [35]. The heterodimer has
a dissociation constant Kd of 19 pmol/m
2 which is grea-
ter than the c chain concentration. This explains why
80 % of c are found in the bound state in cultures of
living cells [36, 37]. The affinity of IL-7R to c is 17-
fold greater than to itself, meaning that formation of the
heterodimer is largely favored and does not limit c bin-
ding. Both heterodimers and homodimers coexist in res-
ting cells [34].
The receptor complex compartmentalizes after IL-7
binding. Interestingly, about 70 % of the proteins recrui-
ted upon IL-7 binding belong to the the cytoskeleton or
are associated with lipid rafts. IL-7 binding drives re-
ceptor complex into lipid rafts. By the other probable
mechanism lipid rafts are formed around the receptor.
The IL-7-IL-7R complex consequently recruits proteins
for the construction of the signaling complex. These
recruited proteins are FERM proteins (ezrin, radixin,
moesin) that anchor the rafted receptor complex to the
cytoskeleton to prevent its diffusion. As far as the lipid
rafts are rich in cholesterol and sphingomyelin, the
membrane thickness is increased. This helps to hold the
long transmembrane domain straight, which in turn
keeps the juxtaposition of the cytoplasmic domains.
The lateral diffusion of lipids and embedded proteins is
reduced by the network of hydrogen bonds between
cholesterol and sphingomyelin and this prolongs IL-
7–IL-7R association, what is essential for the signaling
[38]. The cytoskeleton provides a scaffold for move-
ment of signaling proteins involving complicated ma-
chineries to dispatch signaling molecules to their targets.
IL-7R signaling. Jak/STAT and Src activation. As
it was said, the binding of IL-7 to the IL-7R leads to di-
merization of  and c chains, which brings Jak1 and
Jak3 in close proximity and allows for trans-phospho-
rylation, resulting in the increased kinase activity. Acti-
vated Jak kinases phosphorylate tyrosine residues of the
IL-7R chain ICD that in turn creates docking sites for
SH2 containing proteins. Jak3–/– or the c
–/– knock-out
mice have similar phenotypes as well as IL-7–/– or the
IL-7R–/– knock-out mice. Mutations in Jak3 or the c
chain in humans lead to a T-NK-B+ SCID phenotype [39,
40]. Jak1–/– mice exhibit a severe reduction of T and B
cells, are runt at birth, and die perinatally [41]. IL-7R
phosphorylation is crucial for initiating down-stream
signaling as it leads to the recruitment of STAT proteins
to these phosphorylated residues. Phosphorylation of the
STAT proteins allows them to dimerize and translocate
to the nucleus where they act as transcription factors by
binding to specific promoters [42]. The STAT family
includes seven STAT proteins (STAT 1–4, 5a, 5b and
STAT6). Only STAT1, STAT3, STAT5a and STAT5b
take part in IL-7 signaling [43,44]. STAT1 does not play
a direct role in lymphopoiesis but STAT3 is required,
because a serious reduction in pro-B, pre-B, immature
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Fig. 2. Ribbon diagram of the IL-7R homodimer oriented looking
down onto the cell surface. Chains A and B are colored purple and green,
respectively. The six loop regions involved in the interface and ligand
binding are labeled L1-L6 [34]
and mature B cells, and pro-B cells was observed in
STAT3–/– mice. Additionally, these mice exhibited a de-
crease in proliferative responses to IL-7 [43]. STAT5 is
the main STAT protein activated by IL-7 and mediates
most of the responses of Jak/STAT pathway in cells, in-
cluding the activation of ccnd2, ccnd3, Bcl-2, Bcl-xL,
and Mcl-1 [45,46]. STAT5 is recruited to phoshory-
lated Tyr449 of the IL-7R chain where it is subsequent-
ly phosphorylated by Jak and Src kinases. STAT5a and
STAT5b are absolutely essential for thcell development.
This was proved by using STAT5a/b double deficient
mice, which have been arrested at the pre-pro-B cell sta-
ge. IL-7R–/– mice had similar phenotype [47]. Moreover,
the constitutive activation of STAT5b in IL-7R–/– mice
significantly increased pro-B cells [48]. The use of Rag1-
Cre knock-in mice for conditional mutagenesis of STAT5
in B cells led to complete inactivation of STAT5 which
caused severe defects in the further development of B
cells [49]. IL-7 binding also recruits Src kinases to IL-
7R including both p59fyn and p53lyn. The Src kinase
inhibitors are shown to be involved in impaired prolife-
rative responses to IL-7 [50]. The Src family kinases
play redundant roles during the B cell development and
their function in IL-7 signaling has yet to be fully eluci-
dated. One potential role is to help to activate the STAT
proteins, because Src kinases can directly phosphory-
late the STAT proteins independently or in conjunction
with the Jak proteins [51].
PI3K/Akt and MAPK/Erk pathways. IL-7 binding to
its receptor also leads to activation of phosphatidyl-
inositol 3-kinase (PI3K). PI3K is a heterodimeric protein
built of two subunits: catalytic subunit (p110, p110
or p110) and regulatory subunit (p50, p55 or p85).
P85 of PI3K is also SH2 containing protein which is
recrutred to phosphorylated Tyr449 of IL-7R [52].
Mutations of Tyr499 or the p85 subunit, as well as use of
the PI3K inhibitors, resulted in a loss of the IL-7-indu-
ced proliferation and impaired the B cell development
[53–55]. The p110
–/– and p110
–/– double deficient mi-
ce were arrested at the pre-B cell stage, but showed less
impaired proliferative responses to IL-7, which means
that the p110 and p110 subunits play essential but
redundant roles during B lymphopoiesis [56].
The most important downstream mediator of PI3K
is serine/threonine kinase Akt (PKB). Akt regulates a
large number of pro- and anti-apoptotic factors. One of
the important targets of Akt is the Forkhead box (FoxO)
family of transcription factors (TFs) [57]. Akt phospho-
rylates the FoxO proteins which in turn bind 14–3–3
proteins. The phosphorylation retains them in the cyto-
sol where they are unable to regulate the gene transcrip-
tion. Akt regulates cell survival inducing Bcl-2 and
Bcl-xL, and inhibiting Bad by phosphorylating it and
causing it to be retained in the cytosol where it remains
inactive [58].
IL-7R signaling also involves the MAPK/Erk path-
way. Treatment of pre-B cells with Erk inhibitors as well
as deletion of Erk1/2 in mice blocked the pro-B to pre-B
cell transition and caused a decreased IL-7-induced
pro-B/pre-B cell survival and proliferation. This means
that Erk is an extremely important molecule in IL-7 res-
ponses [54, 57]. Activated Erk proteins translocate to
the nucleus where they phosphorylate a variety of TFs
including Elk and CREB, which in turn induce the ex-
pression of proliferation associated targets llf2, Mef2c,
Mef2d and myc [59]. The adaptor protein Shc also may
be an important mediator in MAPK/Erk pathway be-
cause the pro-B cells containing a defective Shc protein
displayed an increased apoptosis level [60, 61].
IL-7/Jak3/NFATc1 signaling pathway. As it was
mentioned, there are a variety of signaling pathways
mediating the IL-7 influence on cells. These include Jak/
STAT, PI3K/Akt, MAPK/Erk signaling pathways and
there are a huge number of molecules involved in signal
transduction. For instance, the Jak1 and Jak3/STAT5
signaling pathway leads to production of the effector
molecules, such as Bcl-2, which are crucial for T and B
cell progression and proliferation (Fig. 1). The IL-7–
STAT5 pathway is the only critical pathway of the pre-
TCR development of T cells in the thymus [62,63].
However, recently Patra et al. identified the alternative
IL-7/NFATc1 pathway that cooperates with the IL-7/
STAT5 during the thymocyte development [64].
IL-7 signaling was found to activate NFATc1 and fa-
cilitate its translocation to the nucleus, which was inde-
pendent of STAT5 but dependent on the Tyr371 phos-
phorylation of Jak3. NFATc1 is a member of the NFAT
family of transcription factors. NFATc1 is a lymphoid-
specific factor involved in the differentiation and func-
tion of T cells. NFATc1 increases Bcl-2 expression by
cooperating with STAT5, which in turn affects the sur-
vival of thymocytes [65].
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Negative regulators of IL-7 signaling. There are
multiple mechanisms of downregulation of IL-7 signa-
ling, including phosphatases, cytokine-inducible inhi-
bitor molecules, transcriptional suppressors and STAT
degradation. They are necessary for termination of the
signaling of overactive cytokines to prevent autoimmu-
nity or tumourigenicity. SHP-1 is one of the negative re-
gulators of cytokine signaling [66]. SHP-1 can dephos-
phorylate both Jaks as well as activated receptor subu-
nits, depending on the pathway activated [67]. SOCS-1
and CIS-1 have also been identified as suppressors of
cytokine signaling [68]. For instance, SOCS-1 (suppres-
sor of cytokine signaling proteins-1) can inhibit Jak-ki-
nases due to the binding of phosphorylated tyrosine re-
sidues. The cytokine inducible src homology-2 protein
(CIS) binds directly to the activated IL-7R. The protein
inhibitors of activated STATs (PIAS) are proposed to
inactivate STATs. Subsequently, several other members
of inhibitors were found (CIS2-CIS7/ SOCS2-SOCS7)
[68, 69]. Bcl-6 also can bind the STAT docking site on
the receptor ICD and repress the signaling. Additional-
ly, CIS/CIS1 negatively regulates STAT5 activation
[70]. Inhibition of the downstream signaling of Jaks has
been shown to abrogate constitutive STAT3 DNA bin-
ding, inhibit cell proliferation and induce apoptosis in
human breast carcinoma cell lines. Moreover, the ex-
pression of dominant negative STAT3 in these cells in-
duces growth arrest and apoptosis [71]. The degrada-
tion of STAT is another way by which the Jak-STAT
pathway can be negatively regulated [72]. The accumu-
lation of STATs in the nucleus can also be regulated at
the level of nuclear import or/and export [42]. The me-
chanisms that control these processes are not comple-
tely understood.
IL-7R regulation. One of the most important me-
chanisms of regulation of IL-7 signaling is the regula-
tion of the amount of its receptor alpha chain (IL-7R)
present on the surface of the IL-7 dependent cells, as far
as the level of IL-7R directly correlates with the cell
sensitivity to IL-7. The consumption of IL-7 is strictly
controlled by IL-7-induced downregulation of IL-7R,
because of the limiting amount of available IL-7. This
downregulation allows maximizing the total number of
the cells which can receive proliferative and survival
signals of IL-7 [73]. In the absence of IL-7 signaling,
IL-7R expression on the cell surface is regulated by
ephrin molecules (Efn). The deletion of ephrin genes in
T cells, particularly Efnb1 and Efnb2, leads to a de-
creased peripheral naive T cell compartment size. These
Efns stabilize IL-7R expression on T cells interacting
directly with IL-7R [74]. In Efnb1/Efnb2 double de-
ficient T cells upon IL-7 stimulation it was observed a
stronger downregulation of IL-7R, as well as a decrea-
sed STAT5 phosphorylation level. Upon IL-7 stimula-
tion, IL-7R expression on the cell surface is downre-
gulated. Although IL-7R regulation occurs at the trans-
criptional level by multiple mechanisms, it is also re-
gulated at the post-translational level. IL-7R does not
persist stably at the cell surface in the absence of IL-7,
but is rather constantly endocytosed via the clathrin-
coated pits and recycled back to the plasma membrane
[75]. In the absence of IL-7, only a fraction of IL-7R
is degraded through the proteasomal and lysosomal
pathway, with the rest recycled back to the plasma mem-
brane. Upon IL-7 stimulation, the degradation/recyc-
ling ratio is inverted in favor of degradation, leading to
a decreased surface expression of IL-7R [75]. Such an
increased degradation is dependent on the Jak-3 acti-
vity and it concerns only IL-7R, but not the c, as it was
shown by the studies with the human lymphoma T cell
line [75, 76].
Soluble IL-7R. Additonally to relatively well descri-
bed membrane-bound cytokine receptors there are solu-
ble forms of many of them. The functions of soluble
receptors are definitely less understood but they are
known to play an essential role in cytokine biology
[77]. Soluble IL-7R (sIL-7R) circulates at high con-
centration (nmol/mL) compared to IL-7 in healthy hu-
mans (pmol/mL) [78]. Besides, the biologic effects of
sIL7R remain unclear. The biochemical studies show
ed that sIL7R is derived from alternative splicing and
comprises an isoform lacking exon 6 (
6IL-7R) and
having a unique 26-aa sequence [31]. Soluble IL-7R
was reported to block IL-7 signaling. In these studies it
was used the IL-7R-Fc fusion protein, consisting of
the ECD of IL7R and human Fc-fragment, which has
a lower affinity to IL-7 than native sIL-7R. However,
the coadministration of the same molecule, IL7R-Fc,
with IL-7 enhanced antitumor effects compared with
the administration of IL-7 alone in the immunotherapy
model of lung cancer in mice [79]. Complexing IL-7
to anti-IL-7 mAb also enhanced the potency of IL-7 in
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murine models [80, 81]. The next studies have shown
that the competition between IL-7R and sIL-7R ser-
ves to make IL-7 available for all cells according to
their needs. This is possible because sIL-7R binds IL-7
with nanomolar affinity, whereas IL-7R binds it with
picomolar affinity. That is why sIL-7R diminishes
the availability of free IL-7 and modestly compete with
cell-associated IL7R. This results in decreased early sig-
naling, as evidenced by diminished STAT5 phosphory-
lation, but also leads to IL-7 consumption, leading in
turn to overall more enhanced IL-7 effects in the cells
which have limited amounts of IL-7. The coadministra-
tion of sIL7R plus IL-7 increased the half-life of IL-7
in vivo, increased IL-7-mediated homeostatic periphe-
ral expansion of lymphocytes during lymphopenia, and
worsened the severity of experimental autoimmune
encephalitis compared with that in mice receiving IL-7
alone. Howewer, the administration of sIL-7R alone
in the same model had no effect [82]. Thus, the experi-
mental data suggest that sIL-7R plays the role of a car-
rier protein, and that the binding of IL-7 to it potentiates
the biological activity of IL-7.
Conclusions. The review aims to summarize nume-
rous data on the cytokine IL-7 structure, biological ac-
tivity, biological significance and features of functio-
ning studied both in vitro and in vivo. We have made
the main emphasis on the IL-7 potential and conditions
to govern the activity of the appropriate signal transduc-
tion pathways that determine the fate of T and B cells,
as well as LTi cells, NK cells and DCs, which are extre-
mely essential for the development of immunological
reactions of the organism. In our opinion, the literature
analysis in this field reveals a host of questions remai-
ned unanswered so far, and also makes the path for pers-
pective investigation more visible.
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Ó ðåçóëüòàò³ ³ìóíîëîã³÷íèõ äîñë³äæåíü îñòàíí³õ 25 ðîê³â ïîêà-
çàíî, ùî ³íòåðëåéê³í-7 (²Ë-7) º îäíèì ç íàéâàæëèâ³øèõ ðåãóëÿ-
òîðíèõ öèòîê³í³â ³ìóííî¿ ñèñòåìè. Â³í ÷èíèòü çíà÷íèé âïëèâ íà
ðîçâèòîê, ïðîë³ôåðàö³þ ³ àêòèâàö³þ ³ìóííèõ êë³òèí, îäíàê íå íà-
ëåæèòü äî êëàñè÷íèõ öèòîê³í³â-àêòèâàòîð³â, ÿê, íàïðèêëàä, ²Ë-
2, îñê³ëüêè áàãàòî òèï³â êë³òèí ïîòðåáóþòü éîãî ïðèñóòíîñò³
ìàéæå íà âñ³õ ñòàä³ÿõ ðîçâèòêó, à ñïåêòð éîãî àêòèâíîñòåé º
âðàæàþ÷èì. Öåé îãëÿä ìàº íà ìåò³ óçàãàëüíèòè ÷èñëåíí³ äàí³
ùîäî ñòðóêòóðè ²Ë-7, éîãî á³îëîã³÷íî¿ àêòèâíîñò³ ³ îñîáëèâî-
ñòåé ôóíêö³îíóâàííÿ in vitro òà in vivo. Îñíîâíèé àêöåíò çðîáëå-
íî íà øëÿõàõ ñèãíàëüíî¿ òðàíñäóêö³¿ ²Ë-7, ÿê³ âèçíà÷àþòü äîëþ Ò-
³ Â-êë³òèí, à òàêîæ äåÿêèõ ³íøèõ êë³òèí, âàæëèâèõ äëÿ ï³äòðè-
ìàííÿ ãîìåîñòàçó îðãàí³çìó. Àíàë³ç ë³òåðàòóðè ö³º¿ ñôåðè, íà íà-
øó äóìêó, íå ëèøå âèÿâèâ íèçêó ïèòàíü, ÿê³ íàðàç³ íå ìàþòü â³äïî-
â³äåé, àëå é îêðåñëèâ íàïðÿìêè äëÿ ìàéáóòí³õ äîñë³äæåíü.
Êëþ÷îâ³ ñëîâà: öèòîê³í, ³ìóííà ñèñòåìà, ñèãíàëüíà òðàíñ-
äóêö³ÿ, ðåãóëÿö³ÿ.
Ìîëåêóëÿðíûå ìåõàíèçìû ìíîãîñòîðîííåé áèîëîãè÷åñêîé
àêòèâíîñòè èíòåðëåéêèíà-7
À. Â. Ñëèâêà, Î. Â. Îêóíåâ
Ðåçþìå
Â ðåçóëüòàòå èììóíîëîãè÷åñêèõ èññëåäîâàíèé ïîñëåäíèõ 25 ëåò
ïîêàçàíî, ÷òî èíòåðëåéêèí-7 (ÈË-7) ÿâëÿåòñÿ îäíèì èç âàæíåé-
øèõ ðåãóëÿòîðíûõ öèòîêèíîâ èììóííîé ñèñòåìû. Îí îêàçûâàåò
çíà÷èòåëüíîå âëèÿíèå íà ðàçâèòèå, ïðîëèôåðàöèþ è àêòèâàöèþ
èììóííûõ êëåòîê, îíäíàêî íå ïðèíàäëåæèò ê êëàññè÷åñêèì öè-
òîêèíàì-àêòèâàòîðàì, êàê, íàïðèìåð, ÈË-2, ïîñêîëüêó ìíîãî
òèïîâ êëåòîê íóæäàþòñÿ â åãî ïðèñóòñòâèè ïî÷òè íà âñåõ ñòà-
äèÿõ ñâîåãî ðàçâèòèÿ, à ñïåêòð åãî àêòèâíîñòåé âïå÷àòëÿåò.
Öåëü ýòîãî îáçîðà ñîñòîÿëà â îáîùåíèè ìíîãî÷èñëåííûõ äàííûõ
ïî ñòðóêòóðå ÈË-7, åãî áèîëîãè÷åñêîé àêòèâíîñòè è îñîáåííîñ-
òÿì ôóíêöèîíèðîâàíèÿ in vitro è in vivo. Îñíîâíîé àêöåíò ñäåëàí
íà ïóòÿõ ñèãíàëüíîé òðàíñäóêöèè ÈË-7, îïðåäåëÿþùèõ ñóäüáó Ò-
è Â-êëåòîê, à òàêæå íåêîòîðûõ äðóãèõ êëåòîê, âàæíûõ äëÿ ïîä-
äåðæàíèÿ ãîìåîñòàçà îðãàíèçìà. Àíàëèç ëèòåðàòóðû ýòîé ñôå-
ðû, ïî íàøåìó ìíåíèþ, íå òîëüêî âûÿâèë ðÿä âîïðîñîâ, íà êîòî-
ðûå äî ñèõ ïîð íåò îòâåòîâ, íî è î÷åðòèë íàïðàâëåíèÿ äëÿ áóäó-
ùèõ èññëåäîâàíèé.
Êëþ÷åâûå ñëîâà: öèòîêèí, èììóííàÿ ñèñòåìà, ñèãíàëüíàÿ
òðàíñäóêöèÿ, ðåãóëÿöèÿ.
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